Drugs / Pam2CSK4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02124278 | Feb → Oct 2014 | — | Pulmotect, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pam2CSK4 | “Fixed dose combination of Pam2CSK4 acetate (Pam2) and ODN M362 (ODN) administered as an inhalation solution.” NCT02124278 ↗ |
| Known as | Pam2 | “Fixed dose combination of Pam2CSK4 acetate (Pam2) and ODN M362 (ODN) administered as an inhalation solution.” NCT02124278 ↗ |
| Known as | Pam2CSK4 acetate | “Fixed dose combination of Pam2CSK4 acetate (Pam2) and ODN M362 (ODN) administered as an inhalation solution.” NCT02124278 ↗ |
| Route | Inhaled | “Single dose administration by nebulization.” NCT02124278 ↗ |